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ThemoleculardeterminantsofAlzheimer’s(AD)diseasearestillnotcompletelyknown;however,inthepasttwodecades,alarge
body of evidence has indicated that an important contributing factor for the disease is the development of an unbalanced
homeostasis of two signaling cations: calcium (Ca
2þ) and zinc (Zn
2þ). Both ions serve a critical role in the physiological
functioning of the central nervous system, but their brain deregulation promotes amyloid-b dysmetabolism as well as tau
phosphorylation. AD is also characterized by an altered glutamatergic activation, and glutamate can promote both Ca
2þ and
Zn
2þ dyshomeostasis. The two cations can operate synergistically to promote the generation of free radicals that further
intracellular Ca
2þ and Zn
2þ rises and set the stage for a self-perpetuating harmful loop. These phenomena can be the initial
steps in the pathogenic cascade leading to AD, therefore, therapeutic interventions aiming at preventing Ca
2þ and Zn
2þ
dyshomeostasis may offer a great opportunity for disease-modifying strategies.
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Although the majority of Alzheimer’s disease (AD) cases,
referred as sporadic AD (sAD), are idiopathic with no obvious
implication of genetic factors, 5% of all the AD patients show a
Mendelian pattern of inheritance (familial AD, fAD). In both
sAD and fAD, the accumulation of the amyloid-b peptide
(Ab) and neuroﬁbrillary tangles (NFTs) is a key determinant
in AD pathogenesis, the most common form of dementia.
Ab, the main constituent of the amyloid plaques, is a 40–42
amino-acid peptide formed by the proteolytic cleavage of
the membrane-bound amyloid precursor protein (APP)
through the enzymatic activity of the b- and g-secretase
complexes. NFTs are intraneuronal aggregates composed of
hyperphosphorylated tau (h-tau) protein, a peptide that is
involved in stabilizing the microtubular structures of the
cytoskeleton. In addition to Ab dysmetabolism and the
appearance of h-tau deposits, a growing body of evidence
suggests that the deregulation of brain calcium (Ca
2þ) and
zinc (Zn
2þ) homeostasis facilitates the development and
progression of AD.
1–3
Cytosolic Ca
2þ levels ([Ca
2þ]i) are kept in a low range
(B100nM) compared with the levels present in the extra-
cellular space (2mM) or what is found inside of intracellular
stores (100–500mM). These low [Ca
2þ]i are maintained by
the activity of Ca
2þ-binding buffering proteins (e.g., calbindin
and parvalbumin),whereasCa
2þ extrusion isoperatedbythe
Ca
2þ-ATPase pump, and the Na
þ/Ca
2þ exchanger as well
as by the sequestration of the cation in intracellular stores like
the endoplasmic reticulum (ER) and mitochondria. Conver-
sely, [Ca
2þ]i rises are the result ofan inﬂux across the plasma
membrane via store-operated Ca
2þ channels (SOCCs),
voltage-gated Ca
2þ channels (VGCCs), ionotropic glutamate
receptors (N-Methyl-D-Aspartic acid receptors, NMDARs;
a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate, AMPARs)
or the release from intracellular stores. The ER is the largest
intracellular store in neurons and loaded with Ca
2þ at high
concentrations (100–500mM) through the unidirectional
pumping of cytosolic Ca
2þ into the ER lumen, a process
operated by the sarco/endoplasmic reticulum Ca
2þ-ATPase
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www.nature.com/cddis(SERCA) pump. Ca
2þ release from the ER occurs through
the activation of two types of Ca
2þ receptors: the inositol
1,4,5-trisphosphate (IP3R) and the ryanodine (RyR) recep-
tors. Moreover, capacitative calcium entry (CCE), a process
by which the depletion of intracellular Ca
2þ stores causes the
opening of plasma membrane Ca
2þ-permeable channels,
has been described in neuronal subpopulations.
Zn
2þ is the second most abundant metal in the body after
iron (B 3g). Much like [Ca
2þ]i, cytosolic Zn
2þ ([Zn
2þ]i)i s
kept at low concentrations by the combined activity of Zn
2þ
transporters (ZnTs), Zn
2þ-importing proteins (ZIPs), and by
the buffering action of proteins like the metallothioneins (MTs;
reviewedinref.1).Inthecentralnervoussystem(CNS),Zn
2þ
is selectively stored at high levels (B1mM) in presynaptic
vesicles of some, but not all, glutamatergic neurons and
co-released with the neurotransmitter.
4 Thus, during intense
synaptic activity, Zn
2þ can accumulate in the synaptic cleft
and enter postsynaptic spines sharing some entry routes that
are also employed by Ca
2þ (VGCCs, Ca
2þ-permeable
AMPARs (Ca-ARs) and, with less efﬁcacy, NMDARs
1).
Although Ca
2þ and Zn
2þ are involved in a variety of CNS
functions (neurotransmission, mitochondrial functioning, ax-
onal transport, and a plethora of enzymatic activities), their
dysfunctional homeostasis can be a potent trigger for Ab
oligomerization and NFT formation, as well as overproduction
of reactive oxygen species (ROS),
1,3 all of which are factors
critically involved in AD-related neurodegeneration. Further-
more, as both Ca
2þ and Zn
2þ modulate the physiology of
synaptic transmission and plasticity, several lines of evidence
now reveal that the deregulation of the two ions can help to
explain the synaptic dysfunction and cognitive decline
associated with AD.
Thus,giventheimportanceofCa
2þ andZn
2þ homeostasis
for brain functioning, strategies aimed at restoring the brain
balance of these ions are emerging as promising avenues for
the treatment of AD with several therapeutic approaches
based on the so-called ‘metals hypothesis’ already showing
encouraging results.
5,6
However, an important question that still needs to be
addressed concerns the time frame in which such ionic
dyshomeostasis occurs in AD. Does the ionic deregulation
precedeorfollowtheonsetofthepathology?Isthisacauseor
a consequence of the disease?
In this review, we analyze the most recent ﬁndings
indicating the genetic and environmental factors that promote
the early establishment of Ca
2þ and Zn
2þ dyshomeostasis and
show how the process can contribute to AD pathogenesis.
Ca
2þ Dyshomeostasis, Synaptic Dysfunction, and AD
The idea that the perturbation of Ca
2þ homeostasis can have
a pivotal role in the cascading events leading to AD was
introduced more than 20 years ago,
7 and an impressive
amount of evidence obtained from experiments on disso-
ciated cells, brain slices, and, more recently and importantly,
on live AD animal models is strongly supporting this
hypothesis.
8,9
The most important evidence for the ‘Ca
2þ/AD hypothesis’
camefrom alarge numberofstudiesindicatingthatfAD cases
are associated with mutations of three genes: APP,
presenilin-1 (PS1), and presenilin-2 (PS2). Presenilins are
transmembrane proteins synthesized in the ER that have
been shown to greatly affect ER-Ca
2þ dynamics through the
activation of the SERCA pump,
10 via IP3R and RyR open-
ing
11,12 as well as by allowing passive Ca
2þ leakage from the
ER. Notably, all these homeostatic Ca
2þ mechanisms are
foundtobeprofoundlyderegulatedbymutantpresenilinsboth
in vitro and in vivo
9,11,13,14 substantiating the idea that
intraneuronal Ca
2þ deregulation can be part of the patho-
genic cascade leading to AD. Interestingly, a recent study
suggests that PS2 can critically regulate the mitochondrial
uptake of Ca
2þ that is released from the ER, thereby
promoting a potentially harmful cationic overload in the
organelles.
15 Presenilins have also been shown to diminish
CCE in AD neurons and increase Ca
2þ release from
intracellular stores, thereby leading to diminished Ca
2þ
storage.
16 However, another study has reported that AD
neurons show impaired CCE along with augmented store-
dependent Ca
2þ release, as well as increased Ca
2þ
storage.
17 Regardless of the mechanisms involved, it seems
reasonable that a diminished CCE could, in some way,
contribute to AD-related neurodegeneration. Besides their
functions in Ca
2þ homeostasis, PS1 and PS2 may have an
additional role in AD, as they are part of the g-secretase
catalytic domain and presenilin mutations accelerate
(although with different degrees of activity) the production of
‘aggregation-prone’ forms of Ab1 42.
18
Contrary to what has been demonstrated for presenilins,
the role of APP in Ca
2þ deregulation is still controversial.
Whether or not, independently of Ab production, APP can
directly modulate Ca
2þ homeostasis, is still a matter of
debate. Evidence for a direct effects of APP on [Ca
2þ ]i
homeostasis is supported by studies performed on transgenic
mice overexpressing wild-type APP
19 or carrying fAD-linked
APP mutations.
20 These models show neurons undergoing
increased [Ca
2þ]i levels at rest.
20 However, it should not be
overlookedthatconﬂictingresultsalsoindicatetheabsenceof
a direct effect of fAD-linked APP mutations on [Ca
2þ]i levels
and/or Ca
2þ release from intracellular stores.
21,22
Factors linked to sAD are less clear; however, there is
evidence to back the idea that some of them are associated
with [Ca
2þ]i perturbation. For instance, the expression of the
Apoe4 allele that is associated with sAD promotes a strong
increase in [Ca
2þ]i levels by triggering Ca
2þ inﬂux in
neurons.
23 Another sAD risk factor is the presence of a
polymorphism for the Ca
2þ homeostasis modulator 1
(CALHM1) protein, a multipass transmembrane glycoprotein
with a large Ca
2þ conductance across the plasma mem-
brane.
24 The P86L mutation of the peptide decreases
CALHM1-mediated Ca
2þ currents, thereby favoring an
increase in Ab production, which supports the idea that
alterations of speciﬁc Ca
2þ-pools, rather than a global
increase of [Ca
2þ]i, may be critical contributing factors for
AD development and progression.
But how do [Ca
2þ]i alterations inﬂuence the propagation of
the AD-related pathology? The introduction of transgenic
animal models as experimental tools has helped to elucidate,
at least in part, the complex interactions between AD-linked
mutations, ionic deregulation, and the development of Ab and
tau pathology. For example, transgenic mice expressing
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Cell Death and Diseasehuman mutant APP, generate when aging Ab plaques in the
hippocampus and cortex, ultimately mimicking the AD-like
pathology found in patients.
APP processing involves the activation of several Ca
2þ-
dependent proteins and therefore it is likely that increased or
decreased Ca
2þ levels may have aberrant effects on APP
cleavage. For instance, many studies have shown that the
mobilization of different Ca
2þ pools leads to Ab production.
25
To date, the global effect of [Ca
2þ]i rises on Ab levels is still
unclear as some evidence shows that increased [Ca
2þ]i
rises
25–27 promote the production of the non-amyloidogenic
aAPP fragment, but other studies have indicated that [Ca
2þ]i
increases, acting on either the extracellular milieu or
intracellular stores, induce a shift toward the amyloidogenic
pathway.
28Acriticalrevisionofthemostrecentstudiesseems
to support the idea that the homeostasis of the ER-Ca
2þ pool
is crucial in controlling the fate of APP processing.
9–11 In fact,
ER overﬁlling appears to be the ﬁrst clinical sign of the
pathogenic effect of mutant presenilins, a phenomenon
caused by either SERCA overactivation or by the loss of
Ca
2þ leakage, a process ultimately resulting in higher Ca
2þ
efﬂuxthroughRyRsandIP3Rs.Allofthesemechanismshave
been shown to lead to increased Ab secretion.
9–11
It should be noted that there is consensus by which AD can
start as a de-afferentation process, thereby isolating neurons
and promoting synaptic dysfunction. Thus, given the impor-
tance of Ca
2þ signaling in the modulation of synaptic efﬁcacy
and integrity, many investigators have started to explore the
consequences of disrupted intracellular Ca
2þ signaling in the
spines and dendrites of neurons of transgenic AD models. In
thatrespect,ER-Ca
2þ signalingappears,again,tohaveakey
role in modulating synaptic transmission by promoting
presynaptic transmitter release and paired pulse facilitation.
Lending support to this idea, it has been shown that CA1
hippocampal 3 Tg-AD neurons in slices present an aber-
rant, yet seemingly functional, interplay between ER-Ca
2þ
signaling and synaptic transmission, an event that appears
long before the onset of AD-like pathology.
29
A large body of evidence also demonstrates the deleterious
effects of Ab in driving further Ca
2þ deregulation. Many
studies have shown that Ab directly interferes with Ca
2þ
homeostasis and disrupts the activity of ionotropic glutamate
receptors, the P/Q or L-type VGCCs,
30,31 ER-Ca
2þ stores,
32
and CCE,
33 thereby producing increased [Ca
2þ]i levels.
20
Recent in vivo experiments employing multiphoton imaging
indicate that Ab is promoting Ca
2þ deregulation in transgenic
AD neurons, and neurites positioned in the proximity of Ab
plaques,
8 a phenomenon that leads to the downstream
activation of the Ca
2þ-dependent protein phosphatase,
calcineurin.
34 This phenomenon is a key component of the
pathogenic cascade as inhibiting calcineurin with K506
ameliorates dendritic spine density in these animals.
35
Furthermore, several studies indicate that Ab oligomers can
directly induce Ca
2þ entry through the plasma membrane by
promoting the formation of Ca
2þ permeable channels.
36,37
Ionic Deregulation Implication for Synaptic Plasticity
A crucial issue that deserves particular attention is the link
between Ab-driven Ca
2þ deregulation and synaptic efﬁcacy
(long-term potentiation (LTP) and long-term depression
(LTD)). Synaptic loss and dysfunction are the most prominent
pathological features of AD and these processes best
correlate with the development of AD-related cognitive
decline.
38 In vitro and in vivo studies have shown that high
levels of oligomeric Ab can negatively interfere with glutama-
tergic synaptic transmission and plasticity.
39–41 Several
studies have investigated the pathogenic interactions
between altered synaptic Ca
2þ signaling and the aggregation
stateofAb,supportingtheideathatCa
2þ andAbmayinteract
in several different ways to promote synaptic dysfunction.
2
In the past years, the complex interplay between Ca
2þ,
APP, and Ab in the modulation of synaptic transmission and
plasticity has been the subject of a great number of studies.
Through these investigations, it has become clear that Ab can
be secreted in the extracellular space during neuronal
activity
40,42 and that pathologically elevated synaptic Ab
concentrations can alter transmission. Physiological levels
of endogenous Ab may act presynaptically as a positive
regulator to enhance the release probability of synaptic
vesicles of glutamatergic terminals,
43 thereby increasing the
glutamatergic transmission. Conversely, pathologically
elevated Ab concentrations may negatively affect plasticity
by inducing a deﬁcit of NMDAR-mediated excitatory post-
synapticcurrentsaswellasashifttowardNMDAR-dependent
induction of LTD and synaptic loss.
44–48 The process is set by
Ab promoting NMDAR endocytosis and, in this view, Ca
2þ
(through calcineurin activation by Ab) may be considered the
intracellular trigger for Ab–driven synaptic dysfunction.
Supporting this hypothesis, a recent study has proposed an
intriguing mechanism linking Ca
2þ deregulation, Ab dysme-
tabolism, and synaptic dysfunction.
45
According to this study, Ca
2þ inﬂux through synaptic
NMDAR activates at least two pathways that regulate spine
density and postsynaptic responses.
45 On one hand, high
[Ca
2þ]i levels obtained upon tetanic or suprathreshold
synaptic stimulation induce LTP by activating the Ca
2þ/
calmodulin-dependent protein kinase II (CAMKII)-dependent
pathway. On the other hand, low levels of [Ca
2þ]i, obtained
during low-frequency subthreshold stimulation can induce
LTDbyactivatingacalcineurin-dependent pathway(reviewed
in ref. 49). Further evidence indicates effects of Ca
2þ and Ab
on synaptic efﬁcacy and shows that NMDAR-mediated Ca
2þ
inﬂux into active spines is reduced by soluble Ab oligomers,
thereby causing a decrease in spine density via a NMDAR/
calcineurin/coﬁlin-dependent process that leads to LTD.
50
The overall scenario is however more complex as other
studies indicate that Ab oligomers bind to NMDARs and
promote excitotoxic Ca
2þ inﬂux by enhancing NMDAR
activation.
51,52
Further studies have dissected the link between Ca
2þ,
AMPARactivation,andAb-dependentsynapticdysfunction.
44
Acute application of Ab in the dentate gyrus of rat hippocam-
pal slices has been shown to block the activity-dependent
autophosphorylation of CaMKII, thereby leading to reduced
phosphorylation and functioning of the GluA1 subunit of
AMPARs.
53 Another study has shown that soluble Ab
oligomers selectively cause the loss of surface AMPARs.
44
The study suggests that this detrimental process is driven by
Ab binding to Ca-ARs at the dendritic surface and by the
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internalization of Ab and AMPARs.
44
A growing body of evidence also supports the idea that
AD-related neuronal damage may result not only from the
actions of synaptically released Ab, but also derives from the
intraneuronal accumulation of the peptide. It is known that
elevated intraneuronal Ab immunoreactivity precedes the
appearance of plaques and better correlates with the onset of
the synaptic and behavioral abnormalities shown in trans-
genic AD models.
54 Moreover, in neuronal cultures, the
depolarization and subsequent Ca
2þ-mediated transient
phosphorylation of both tau and APP induce the accumulation
of intraneuronal Ab.
55 However, decreased synaptic activity
has also been shown to be detrimental by promoting an
increase in intracellular Ab that is followed by synaptic
damage.
56,57
As far as tau-dependent pathology, in recent years
evidence strongly substantiates the idea that Ca
2þ deregula-
tion is also involved in NFTs formation. This phenomenon is
particularly relevant given the renewed interest in the
pathogenic action of tau pathology in promoting neurode-
generation and cognitive decline in AD.
58
It should be remembered that the anatomical distribution of
NFTsfollows atypical spreading pathwaythat, comparedwith
the distribution of Ab pathology, correlates in a better way with
the progression of AD symptoms. Recent evidence is in fact
starting to question the exact sequence of events previously
described in the ‘Ab amyloid cascade hypothesis’ and
suggests that, in fact, Ab-mediated toxicity is largely
modulated (and not in a secondary way) by tau-dependent
processes.
59–61 For instance, a recent study has shown that
somehippocampalculturedneuronsexposedtoAboligomers
relocate tau from axons to cell bodies and dendrites.
61
Interestingly, this Ab-driven dendritic missorting of tau
appears to be the key to promote downstream pathogenic
events like dendritic Ca
2þ rises, changes in tau phosphoryla-
tion, loss of spines and mitochondria, and relocation of other
cytoskeletal elements, as well as changes in the activity of
crucial kinases.
61 A similar change in tau distribution and
phosphorylation has been shown in neurons exposed to
oxidative or excitotoxic stress, suggesting a common signal-
ing cascade that culminates in regional tau pathology and
eventually in the breakdown of neuronal architecture.
61
Furthermore, recent evidence has linked tau dysmetabolism
to Ab-dependent excitotoxic damage.
60,62 According to this
model, tau is moving to dendrites, promoting the activation of
a Src kinase (Fyn), and leading to the phosphorylation of the
GluN2B NMDAR subunit. This process facilitates the interac-
tion of NMDARs with the scaffolding protein PSD-95,
increasing the stability of NMDARs within the PSD, thereby
coupling the receptors to Ab-dependent excitotoxic signaling.
The full extent by which tau dyshomeostasis mediates
synaptic transmission, neuronal degeneration, or both, is
actually matter of an exciting current debate
58,63 and new
intriguingevidenceisemerging.Forinstance,geneticdeletion
of tau completely prevents the deleterious effects on LTP
elicited by the exposure to either human or rodent Ab1–42,
thereby suggesting that the protein is instrumental for the
development of the synaptotoxic effects of Ab.
64 Moreover,
tau-induced defects in synaptic plasticity are reversible in
transgenic conditional mice after switching off the toxic tau
mutant.
63 Data linking Ca
2þ dyshomeostasis with the
neurotoxic effects of a tau fragment of 17 kD are associated
with calpain activation.
65 Interestingly, another study has
shown that [Ca
2þ]i rises evoked by glutamate or thapsigargin
(a SERCA inhibitor) are also able to promote the same
cleavage of this ‘17 kD’ fragment, thereby conﬁrming the
Ca
2þ dependency of the phenomenon.
66
Further studies are lending support to the idea that
AD-related alterations have an important role in altering
glutamate neurotransmission (and indeed, AD patients are
now treated with memantine, a low-afﬁnity NMDAR blocker).
As described above, a major source for [Ca
2þ]i rises results
from the overactivationof glutamatergic receptors, a phenom-
enon that occurs in experimental models of AD and triggers
robust oxidative stress.
20 It is worth noticing that Ab itself
can increase glutamatergic neurotransmission and render
neurons more vulnerable to excitotoxicity by interfering with
glutamate re-uptake.
67
As both Ab and h-tau further facilitate Ca
2þ dyshomeostasis,
the process appears to take the shape of an injurious cycle that
leads to AD-related synaptic dysfunction and neuronal death.
Thus, glutamate and Ab can operate synergistically to
promote oxidative stress and set the stage for a self-
perpetuating harmful loop. Oxidative stress can also enhance
tau phosphorylation and tau-dependent pathology that further
exacerbates Ab-driven pathology
68 (Figure 1). It should also
be noted that, suggesting a feed forward process, recent data
indicatethatinjectionofoligomers,obtainedfromthecortexof
AD patients, triggers tau hyperphosphorylation, disrupts the
microtubule architecture, and sets in motion neuritic dystro-
phy.
69 Finally, NMDAR activation can also promote the
intraneuronal release of Zn
2þ, thereby suggesting a patho-
genic link between the dyshomeostasis of the two cations
70
(Figure 2).
Zn
2þ Deregulation, Synaptic Functioning, and AD
Like Ca
2þ,Z n
2þ is involved in a wide array of physiological
functions
1 and, as with Ca
2þ, the deregulation of intracellular
Zn
2þ ([Zn
2þ]i) has an important role in AD.
The mammalian brain contains a pool of loosely bound
Zn
2þ also deﬁned as ‘chelatable Zn
2þ’.
1 Zn
2þ-containing
neurons form a complex and elaborate associational network
that interconnects most of the cerebral cortices and limbic
structures and Zn
2þ-containing axon terminals are particu-
larly abundant in the neocortex and hippocampus.
Zn
2þ is often localized within synaptic vesicles of a subset
of glutamatergic axon terminals, although there is also
evidence indicating enrichment of Zn
2þ at selected inhibitory
g-Aminobutyric Acid (GABA) terminals in the cerebellum and
spinal cord.
71,72 In the subpopulation of glutamatergic
neurons, Zn
2þ is transported into small, clear, and round
presynaptic vesicles by the neuronal-speciﬁc Zn
2þ transpor-
ter, ZnT3, throughout a process that stores the cation inside
vesicles together with glutamate.
1 Thus, Zn
2þ and glutamate
are co-released in the synaptic cleft during neuronal activity.
Previous studies showed that sustained stimulation of
hippocampal mossy ﬁbers (MFs), a brain structure that shows
the strongest Zn
2þ amount in the brain, produces a great
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2þ levels and more recent evidence
hasdemonstratedthatsuchsynapticZn
2þ isaprincipalfactor
in modulating neurotransmission.
1
Bothexcitatory ionotropic glutamatereceptors(iGluRs) and
inhibitory ionotropic receptors (GABAA) are affected by
Zn
2þ.
73 The best characterized synaptic Zn
2þ target is
represented by the NMDAR. Zn
2þ modulates NMDAR
properties through a dual mechanism: low micromolar
concentrations selectively inhibit NMDAR-mediated currents
through a voltage-independent, non-competitive (allosteric)
inhibition whereas high Zn
2þ concentrations (more than
20mM) are responsible of a voltage-dependent inhibition of
the receptor-mediated currents.
74–76 The N-Terminal-Domain
(NTD) of the NMDAR GluN2A subunit binds Zn
2þ with high
(nanomolar) afﬁnity and this high sensitivity to Zn
2þ has
important consequences. The most relevant is that synaptic
Zn
2þ can exert its modulatory effects not only during fast
phasic synaptic release but also in a tonic mode. In other
words, under normal resting conditions, the GluN2A-speciﬁc
Zn
2þ binding site can be partially occupied by the cation,
thereby inhibiting the receptor.
75 Interestingly, Zn
2þ inhibition
can be also maximized by the tyrosine kinase src-mediated
phosphorylation of the receptor.
77 AMPARs are also sensitive
toextracellularZn
2þ,
78however,thephenomenonappearsto
require higher (micromolar) Zn
2þ levels.
In addition to ionotropic receptors, synaptically released
Zn
2þ modulates the activity of key synaptic proteins. For
instance, Zn
2þ can interfere with the biochemical activity of
proteinslikeglutamatetransportersandmatrixmetalloproteinases
Figure 2 Glutamate receptor activation: a link between Ca
2þ and Zn
2þ
dyshomeostasis. NMDAR activation promotes a Ca
2þ dependent release of
intraneuronal Zn
2þ.( a) Neuronal cultures, loaded with the Zn
2þ-sensitive (but
Ca
2þ-insensitive) ﬂuorescent probe, FluoZin-3, are shown, before, during, and
after a 10min exposure to NMDA (50mM), in a Ca
2þ containing (black) or
nominally Ca
2þ free (red) buffer. (b) Pseudocolor images of FluoZin-3 ﬂuorescent
changes upon the experimental condition described in A. Note that the addition of
the Zn
2þ chelator compound, TPEN, completely quenches the FluoZin-3
ﬂuorescence changes,demonstratingtheZn
2þ dependency ofthesignal(modiﬁed
from ref 70)
Figure 1 Ab, oxidative stress, tau, glutamate receptor overactivation, Ca
2þ, and Zn
2þ dyshomeostasis may synergistically promote AD-related synaptic and neuronal
loss.ThesequestrationofZn
2þ bytheamyloidcontainedinextracellularplaques(1)mayremovethecationfromthesynapticcleftandreleasetheZn
2þ-dependentNMDAR
blockade(1). Ab also directly activates Ca-ARs (2). Both phenomena promote Ca
2þ overload,increased superoxide generation from mitochondria (3), as well as nitric oxide
(NO) production from Ca
2þ-dependent activation of NO synthase(NOS) (4). Reactive oxygen and nitrosative species (ROS and RNS) then mobilize Zn
2þ from MTs leading
to toxic Zn
2þ concentrations (5) that further impair mitochondrial function, promote more ROS generation (6), and release pro-apoptotic factors (7). ROS-driven Zn
2þ
mobilization may also facilitate intra-neuronal Ab aggregation (8). Ab may amplify this vicious loop by increasing the generation of ROS that when extracellularly released
reduce glutamate reuptake (9) and overactivate NMDARs and Ca-ARs. Mutant PS1 and APP enhance Ca
2þ dyshomeostasis by altering the ER-mitochondrial network (10).
NMDAR-mediated [Ca
2þ]i rises and oxidative stress may also accelerate tau hyperphosphorylation (11) and recent evidence indicates that oligomers from AD patients are
directly promoting tau hyperphosphorylation as well (12). Zn
2þ sequestration also impairs BDNF signaling (13) (by blocking TrkB and or MMPs), and also reduces the
modulating effects exerted by the activation of its own ZnR (14). All these processes, set in motion at the level of synaptic spines, may be the primum movens of synaptic
dysfunction, neuronal deafferentation, and death
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Cell Death and Disease(MMPs)inphysiologicalandpathologicalconditions(Figure3).
79
Furthermore, a recent study indicates a novel mechanism by
which Zn
2þ can modulate synaptic functions as the cation is
able to activate mitogen-activated protein kinase (MAPK) and
CaMKII by acting on a putative Zn
2þ-sensing receptor (ZnR).
80
A recent study has also shown that Zn
2þ transactivates the
tropomyosin-related kinase B (TrkB) receptor (the receptor
responsive to the brain-derived neurotrophic factor (BDNF))
and activates BDNF signaling in a neurotrophin-independent
manner.
81 Furthermore, Zn
2þ also affects BDNF signaling by
promoting the maturation of pro-BDNF to BDNF throughout
the activation of MMPs
82 and this phenomenon has been
recently validated in animal AD model (Figure 3).
79 It is also
important to underline that the non-amyloidogenic APP
processing is mediated by membrane-anchored Zn
2þ-
dependent metalloproteinases like the ones belonging to the
ADAM family [a disintegrin and metalloproteinases,
83]a
phenomenon that suggests that [Zn
2þ]i might also have a
role in regulating the balance between amyloidogenic and
non-amyloidogenic pathways.
Finally, intracellular Zn
2þ can interfere with neuronal
excitability by modulating the activity of the neuronal K
þ
transporter, KCCN, a key controller of the neuronal resting
membrane voltage potential.
84 Thus, the speciﬁc localization
of Zn
2þ at certain glutamatergic synapses, together with its
multiple synaptic targets, makes the cation a very attractive
candidate as an endogenous modulator of synaptic transmis-
sion and plasticity; however, deregulated Zn
2þ homeostasis
also appears to be a strong promoter of AD development
(Figure 4).
Indeed, there are no doubts that a complex alteration of
transportation and distribution occurs in the AD brain and that
alterations of synaptic Zn
2þ are key factors in promoting
AD-like pathology. Lending support to this idea, a study has
shown that aging is associated with the development of
decreased brain levels of ZnT3, a phenomenon that is
enhanced in AD brains.
85 ZnT3 downregulation leads to a
deﬁcit in synaptic Zn
2þ that is associated with a strong
downregulation of synaptic proteins that are important for
memory and learning processes.
85 Interestingly, another
Figure 3 Zn
2þ supplementation isbeneﬁcialinanimalmodelofAD.(A)Zn
2þ supplementationpreventsthedevelopmentofhippocampus-dependentmemorydeﬁcitsin
3 Tg-ADmice.3 Tg-ADmiceweretreatedwitheitherwatercontaining30p.p.m.ofZnSO4ortapwaterfor11–13monthsandtestedforthespatialmemoryversionofthe
MWM. Mice were tested when the platform was removed 1.5h (to investigate short-term memory) and 24h (to investigate long-term memory) after the last training trial.
Comparedwithuntreated3 Tg-ADmice,Zn
2þ-fed3 Tg-ADmicedid notshowany signiﬁcantdifferenceintheirshort-termmemoryperformance,butexhibitedamarked
recovery in their long-term memory as indicated by the decreased time (latency) they employed to reach the point where the platform used to be (Error bars indicate mean
values±S.E.M.;*Po0.05).(B)Zn
2þ supplementationreducesbothAbandtaupathologyinthehippocampusof3 Tg-ADmice.Immunohistochemistryshowsdepositsof
intraneuronal Ab (a–d) and h-tau (f–j) in brain slices from treated and untreated 3 Tg-AD mice (left column: 20  magniﬁcation; right column: 40  magniﬁcation).
Compared with untreated mice (a, b), treated 3 Tg-AD mice showed a signiﬁcant decrease of intraneuronal Ab deposits in the hippocampus of (c, d). (b, d)  40
magniﬁcation of the hippocampal CA1 area as shown in the rectangle. (e) Quantiﬁcation of Ab load as shown in a and c. Compared with untreated mice (f, g), Zn
2þ-fed
3 Tg-AD mice showed a strong decrease of intraneuronal h-tau immunoreactivity in the hippocampus of (h, i). (g, i)  40 magniﬁcation of the CA1 area as shown in the
rectangle.(j)Quantiﬁcationofh-taulevelsfromfandh.Errorbarsindicatemeanvalues±S.E.M.;*Po0.05.(C)Zn
2þ supplementationpromotesMMPsactivationin3 Tg-
AD mice. (a) Gelatine zimography indicates that Zn
2þ feeding induced a signiﬁcant increase of MMP-2 and MMP-9 activation in 3 Tg-AD mice brains. (D). Zn
2þ
supplementation increased brain BDNF levels. BNDF immunoblotting reveals that Zn
2þ-treated 3 Tg-AD mice showed a fourfold increase in BDNF levels when compared
with untreated animals. *Po0.05; **Po0.01. Error bars indicate mean values±S.E.M. (modiﬁed from ref. 79)
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Cell Death and Diseasestudy has indicated that ZnT3-KO mice show a reduced
activity-dependent induction of Erk1/2 signaling at the MF
presynapticterminals.SuchdiminishedErk1/2activityderives
from the lack of inhibition of the Zn
2þ-sensitive MAPK
tyrosine phosphatase, thereby suggesting that an increased
synaptic release of the cation from MFs on learning might
enhance the inhibition of tyrosine phosphatases leading to
further presynaptic Erk activation. Consistent with this
prediction, ZnT3-KO animals show cognitive deﬁcits.
86
A deﬁcit of synaptic Zn
2þ has also been associated with
decreased brain levels of BDNF and other neurotrophins as
well as with the development of severe cognitive decline.
85
Moreover, data obtained from acute murine hippocampal
slices indicate that synaptic Zn
2þ facilitates the binding of Ab
oligomers to the GluN2B subunit of the NMDAR in MF
terminals and interferes with glutamatergic transmission.
87
Furthermore, notable studies by Lovell and colleagues have
shown alterations in the expression of the Zn
2þ transporters,
ZnT4, ZnT1, and ZnT6 in the brain of preclinical and early-
stage AD patients, suggesting a concurrent causative role of
early Zn
2þ-dyshomeostasis in triggering AD-related patho-
genic events.
88,89
A strong link between Zn
2þ and Ab in AD is also conﬁrmed
by several observations: (1) amyloid plaques are highly
enriched in Zn
2þ (ref 90); (2) genetic ablation of synaptic
Zn
2þ prevents Ab deposition;
91 (3) trace concentrations of
Zn
2þ, as well as Cu
2þ or Fe
3þ are sufﬁcient to induce Ab
nucleation and eventually the ﬁbrilization of the peptide;
92,93
(4) Zn
2þ enhances Ab aggregation and precipitation during
AD progression whereas Zn
2þ chelators induce a rapid
resolubilization of Ab deposits in post-mortem AD brain
samples.
94
Zn
2þ also critically modulates amyloid metabolism.
1
Indeed, both APP and Ab speciﬁcally bind Zn
2þ, with APP
having a binding site for zinc (KD¼750nM) in the cysteine-
rich region of the APP ectodomain,
95 and Ab exhibiting both a
high-afﬁnity binding site (KD¼107nM; with a 1:1 (Zn
2þ/Ab)
stoichiometry) as well as a lower-afﬁnity binding site
(KD¼5.2mM; with a 2:1 stoichiometry
92). Subtle changes in
Zn
2þ and Ab brain levels appear therefore crucial in
determining a shift from a physiology to pathology (Figure 4).
As mentioned, the brain has one of the highest content of
Zn
2þ with an overall concentration of B150mM. (ref. 1) Some
forebrain neurons store up to 200–600mMo fZ n
2þ in synaptic
vesicles and release B1–10% of this amount as freely
exchangeable Zn
2þ. However, in a healthy brain, the
exchangeable amount of Zn
2þ in the extracellular ﬂuid is
approximately 1–10nM whereas the free cytosolic [Zn
2þ]i
levels are in the sub-nanomolar range. Ab is a physiological
component of the CSF and normally produced and secreted
during cell metabolism at nanomolar concentrations and then
quickly degraded (reviewed in ref. 96).
Very little is known on the exact dynamics of the Ab
intracellular pool. Indeed, although an increasing body of
evidenceindicatesthatAbaccumulatesintracellularly, itisstill
not clear whether this accumulation is the result of a failure of
Ab secretion, or whether secreted Ab is taken back by the cell
to build up intracellular pools.
96 While under physiological
conditions (especiallyifoneconsiderstheAbKDforthehigher
afﬁnity binding site), [Zn
2þ]i levels are likely too low to
promote signiﬁcant complex formation with Ab. However,
[Zn
2þ]i release occurring under oxidative stress might
promote sufﬁcient cation levels to initiate Ab oligomerization.
Such ROS-dependent intraneuronal [Zn
2þ]i rises have been
found to be particularly high in AD neurons expressing mutant
APP, PS1 and h-tau.
97
To date, a precise understanding of how Ab forms
complexes with Zn
2þ and/or other metal ions is still largely
unknown. Even though monomeric Ab has been shown to
form a complex with Zn
2þ, large oligomeric assemblies seem
to be preferentially precipitated upon coordination with the
cation.
98 The N-terminal region of different Ab oligomeric
populations can access a range of metal-coordination
structures,
98 therebyleadingto anextensivepolymorphism.
99
It is important to underline that these polymorphic species
include antiparallel b-sheet conformations
100 increasingly
recognized as ‘signature’ structures of toxic Ab oligomers.
101
The neurotoxic fate of these aggregates varies. Depending
on their relative stabilities and energy landscapes, some
intermediates can be selectively stabilized or precipitated
intoinsoluble,inertﬁbrilsbyZn
2þ (ref.100,102).Thescenario
changes when they get conjugated with metals. Indeed,
high [Zn
2þ]i levels can promote Ab-induced toxicity both
in vitro (at 50mM)
103 and in vivo (at 1mM),
104 when
considering equimolar Ab/Zn
2þ concentrations. These ﬁnd-
ingssuggestthathigh[Zn
2þ]risesmaypreferentiallyinducea
stabilization of small, soluble, toxic intermediates that remain
for a longer time in solution without necessarily evolving
into ﬁbrils.
100 However, a neuroprotective effect can also be
seen at lower Zn
2þconcentrations ((5–0.5mM; in the case of
Ab/Zn
2þ molar ratios of 1:0.1 and 1:0.01
102,103). In contrast
to high Zn
2þ levels, low Zn
2þ concentrations can selectively
Figure4 Alterationsofthe‘zincsetpoint’,implicationsforAD.Themaintenance
of brain Zn
2þ homeostasis is crucial for neuronal functioning. Perturbations of this
equilibrium may be a contributing factor in AD development and progression.
Excessive Zn
2þ facilitates Ab oligomerization as well as overproduction of reactive
oxygenspecies(ROS),therebypromotingsynapticdysfunctionandneuronaldeath.
However, Zn
2þ deﬁciency may also be deleterious as decreased bioavailability of
the cation leads to reduced activation of neuroprotective BDNF signaling. Zn
2þ
deﬁciency in fact decreases the maturation of pro-BDNF to BDNF and reduces the
transactivation of the BNDF receptor, TrkB. Moreover, decreased levels of brain
Zn
2þ canfurtherdownregulatetheexpressionand/ortheactivityofneuroprotective
Zn
2þ-dependent proteins that are involved in Ab clearance (e.g., MMPs) or free
radical scavenging (e.g., MTs). Finally, synaptic Zn
2þdeﬁciency also leads to
neurotoxic activation of NMDARs
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Cell Death and Diseasedestabilize larger soluble intermediates by lowering their
kinetic barriers toward the formation of precipitates.
102
This concentration-dependent activity of Zn
2þ in the modula-
tion of Ab-associated neurotoxicity has been considered a
paradox.
105
Besides its activity on Ab,Z n
2þ also promotes tau
aggregation
106 and it should be noted that NFT-bearing
neurons contain abnormally high (millimolar) levels of
Zn
2þ.
107 Similarly to what is seen with the Ab-Zn
2þ complex,
Zn
2þ also binds to single tau monomers with a moderate
(micromolar) afﬁnity (KD¼3.8mM). Interestingly, under redu-
cing conditions, tau ﬁbrilization depends on [Zn
2þ] levels as
low Zn
2þ (10mM) accelerates the process (with a tau/Zn
2þ
molar ratio of 1:1) whereas higher levels (100mM) have
opposite effects (with a tau/Zn
2þ molar ratio of 0.1:1
106).
Finally, Zn
2þ also exerts a bimodal effect on tau phosphor-
ylation, with high Zn
2þ levels inducing tau hyperphosphoryla-
tion through the activation of glycogen synthase kinase 3b
and low Zn
2þ concentrations promoting tau dephos-
phorylation.
79,108
Ca
2þ and Zn
2þ Dyshomeostasis: a Synergy that
Produces a Potentially Self-perpetuating Pathogenic
Loop
In the complex scenario of AD, all the factors previously
mentioned, Ab, oxidative stress, tau, glutamate receptor
overactivation, Ca
2þ, and Zn
2þ dyshomeostasis may act in
concert to promote synaptic loss and, ultimately, neuronal
loss (Figure 1). Zn
2þ sequestration by Ab in extracellular
amyloid plaques promotes an over-activation of NMDARs,
whereas Ab directly activates Ca-ARs and the two phenom-
ena lead to Ca
2þ overload, increased superoxide generation
from NADPH oxidase and mitochondria as well as nitric oxide
(NO) production from Ca
2þ-dependent activation of NO
synthase (NOS). Ca
2þ-dependent production of reactive
oxygen and nitrosative species (ROS and RNS) then mobilize
Zn
2þ from MTs leading to toxic Zn
2þ concentrations. These
Zn
2þ rises impair mitochondrial function, promote further
ROS generation,
109 and release pro-apoptotic factors. ROS-
driven Zn
2þ mobilization may then promote intraneuronal Ab
aggregation. Ab may amplify the damaging results of this
vicious cycle by increasing oxidative stress, reducing gluta-
mate reuptake and inducing the activation of NMDARs and
Ca-ARs. Furthermore, glutamate-driven mitochondrial Ca
2þ
overload mobilizes Zn
2þ from these organelles,
70 thereby
increasing toxic cytosolic Zn
2þ levels. PS1 and APP
mutations may enhance these pathways by contributing to
Ca
2þ dyshomeostasis via increased Ca
2þ release from the
ER-mitochondrial network.
[Ca
2þ ]i rises and oxidative stress also enhance
neuronal damage by interfering with tau hyperphos-
phorylation.
61,110 In that respect, NMDAR overactivation,
Ca
2þ overload, and the resultant increased superoxide
generation may all favor and increase tau hyperphos-
phorylation.
All these processes, set in motion at the level of synaptic
spines, may be the primum movens of synaptic dysfunction,
neuronal deafferentation, and death.
Ionic Dyshomeostasis as Potential Therapeutic Target
Consistent with the idea that AD may involve a chronic
deregulation in the homeostasis of Ca
2þand Zn
2þ, several
therapeutic strategies have aimed at restoring physiological
cationic signaling in an effort to counteract the development
andprogression ofthe disease. For example,recent evidence
points toa possible therapeutic role forCa
2þ chelation, asthe
cation may have an important role in stabilizing the
g-secretase complex, as conﬁrmed by recent observations
showing that EGTA and EDTA reduce its activity.
111
Furthermore, targeting NMDAR-mediated Ca
2þ inﬂux has
produced a promising anti-AD drug. Memantine, an uncom-
petitive and moderate-afﬁnity NMDAR antagonist, protects
neurons against Ab-related toxicity,
112 reduces AD-like
pathology in transgenic mice,
113 and appears to be an
effective, safe, and well-tolerated treatment for moderate-to-
severe AD.
114 Great attention has also been paid toward the
activity of antagonists of a speciﬁc NMDAR subunit. Ifenprodil
and Ro 25–6981, two compounds that selectively target
NMDAR containing the GluN2B subunit protect neurons from
Ab-induced synaptic plasticity impairment.
115 Furthermore,
EVT-101 (Evotec AG, Hamburg, Germany; http://www.
evotec.com/), a newly developed GluN2B antagonist, has been
shown to improve the cognitive performance of AD patients and
has less side effects when compared with memantine.
In the past few years, efforts have also been made to
address AD-related Zn
2þ dyshomeostasis. To date, the most
promising class of drugs developed for counteracting Zn
2þ
deregulation are the so called metal-protein attenuation
compounds (MPACs). MPACs aim at removing Zn
2þ from
Ab and relocate the cation to sites where it can be beneﬁcial,
like for instance the TrkB receptor or the MMPs, thereby
increasing BDNF signaling. Among the MPACs, the lipophilic
quinoline derivative, PBT2, has shown the most promising
results by serving as metal exchanger and ionophore. In AD
murine models, PBT2 restores cognition, strongly reduces
interstitial Ab, restores spine density, and preserves the
maintenance of crucial synaptic proteins.
116,117 In AD
patients, PBT2 reduces CSF Ab levels and promotes
cognitive improvement.
5,6 Interestingly, a dual, Ca
2þ and
Zn
2þ, modulator compound, DP-109, is also effective in
reducing Ab load and cognitive deﬁcits in AD mice.
118 The
effect of DP-109 is most likely due to removal of Zn
2þ from
amyloid plaques as well as its capability to restore intra-
neuronal Ca
2þ homeostasis; however, the full spectrum of its
actions is still largely unknown.
Finally, the issue of handling AD-dependent Zn
2þ dereg-
ulation also poses the question of when and how to intervene.
While it is now clear that, in a symptomatic phase of the
disease, therapeutic strategies aimed at restoring Zn
2þ
homeostasis should favor the de-sequestration of Zn
2þ from
plaques and its relocation from injurious to beneﬁcial sites,
early stage intervention may actually take advantage by the
daily supplementation of small quantities of Zn
2þ. In that
respect, a recent study in a transgenic AD model, indicates
that restoring brain Zn
2þ levels with dietary supplementation
in a pre-symptomatic stage of the disease can effectively
counteract the development of hippocampus-dependent
cognitive deﬁcits.
79 The beneﬁcial effects of Zn
2þ
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Cell Death and Diseasesupplementationappearto belinked tothe actionofthe cation
in increasing BDNF levels and by its activity in counteracting
age-dependent mitochondrial dysfunction
79 (Figure 3).
In summary,a better understandingof the complex network
linking the AD-dependent deregulation of these two cations
poses great challenges but also offers the potential for the
development of effective disease-modifying drugs.
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